New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia by W. HiddemannNew Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia by W. Hiddemann

New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

EditorW. Hiddemann, R. Mertelsmann

Paperback | August 22, 1990

Pricing and Purchase Info

$148.02 online 
$167.95 list price save 11%
Earn 740 plum® points

In stock online

Ships free on orders over $25

Not available in stores

about

This book provides a unique overview of the current applications of aclacinomycin A in malignant hematologic disorders, as single-agent therapy or together with other agents in combination regimens. Accounts are given of its action in myelodysplastic syndromes and of its efficacy in acute myeloid leukemias for the latter, one chapter presents the results of single-agent therapy in older patients, while four other studies describe the efficacy of aclacinomycin A combined with conventional or intermediate-dose cytosine arabinoside or etoposide in relapsed or refractory acute myeloid leukemia.
Title:New Findings on Aclarubicin in the Treatment of Acute Myeloid LeukemiaFormat:PaperbackDimensions:61 pages, 9.25 × 6.1 × 0.03 inPublished:August 22, 1990Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3540526137

ISBN - 13:9783540526131

Look for similar items by category:

Customer Reviews of New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

Reviews

Table of Contents

Contents: Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia.- Low-Dose Aclacinomycin and Intermediate-Dose Cytosine - Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia.- Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin Plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial.- Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia.- Aclarubicin in the Treatment of Refractory Acute Leukemias.- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie.- Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study.- Sachverzeichnis.